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Asthma and chronic obstructive pulmonary disease are inflammatory airway diseases 
for which alternative therapeutic strategies are urgently needed. Interestingly, 
HDAC inhibitors show anti-inflammatory effects in mouse models for these diseases. 
Here we explore underlying mechanisms that may explain these effects. In previous 
studies, effects of HDAC inhibitors on histone acetylation are often correlated with 
their effects on gene expression. However, effects of HDAC inhibitors on transcription 
factors and their acetylation status may be particularly important in explaining these 
effects. These effects are also cell type-specific. Recent developments (including 
chemoproteomics and acetylomics) allow for a more detailed understanding of 
the selectivity of HDAC inhibitors, which will drive their further development into 
applications in inflammatory airway diseases.
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Asthma and chronic obstructive pulmonary 
disease (COPD) are common inflamma-
tory airway diseases. These diseases affect 
millions of people world-wide, and globally, 
the incidence is increasing. For asthma, the 
clinical symptoms include among others 
wheezing and shortness of breath. COPD 
is characterized by shortness of breath upon 
exercise and a largely irreversible and progres-
sive airflow limitation [1–4]. In asthma the 
larger airways are mainly affected, whereas 
in COPD, the lung parenchyma and periph-
eral airways are mainly affected [3]. The 
immunopathology of asthma and COPD is 
characterized by different types of inflam-
matory cells that are at play. For example, 
asthma is driven by T helper 2 (T
h
2) cells, 
dendritic cells and is characterized by eosin-
ophilic inflammation. In asthma there is 
mast-cell sensitization by immunoglobulin 
E (IgE), and multiple bronchoconstrictors 
are released [1,2]. On the other hand, COPD 
is characterized by T helper 1 (T
h
1) cells, 
cytotoxic T cells and neutrophilic inflamma-
tion [5,3]. The inflammation in COPD is also 
characterized by increased numbers of mac-
rophages, neutrophils and innate lymphoid 
cells recruited from the circulation. A vari-
ety of pro-inflammatory mediators, includ-
ing cytokines, chemokines, growth factors 
and lipid mediators are secreted by these cell 
types [5]. Currently, glucocorticoids are the 
cornerstone in the treatment of asthma and 
COPD, however, this is not effective in all 
patients. Severe asthmatics display gluco-
corticoid resistance [6], and the effectivity of 
glucocorticoids in COPD patients is subject 
to debate [7,8]. Alternative therapeutic strate-
gies are needed for these patients, which cur-
rently form a major health burden for soci-
ety due to high socioeconomic costs [1–4,9]. 
Studying the underlying molecular mecha-
nisms may enable the identification of new 
therapeutic targets.
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These underlying processes may include epigenetic 
regulation, such as lysine acetylation. Lysine acetyla-
tion is a post-translational modification of proteins, 
which is crucial in the regulation of cellular processes 
such as signal transduction and gene expression [10,11]. 
Lysine acetylation was initially discovered as a modi-
fication of histone proteins [12], where it plays a role 
in facilitating an open chromatin structure and gene 
transcription [13]. Lysine acetylation is regulated by 
histone acetyltransferases (HATs, also known as lysine 
acetyltransferases or KATs) as writers and histone 
deacetylases (HDACs, also known as lysine deacety-
lases or KDACs) as erasers. Dysregulation in the bal-
ance between the activities of HDACs and HATs can 
result in disease, such as inflammatory diseases and 
cancer [14–17]. Mammalian HDACs are classified into 
four main groups based on their homology with yeast 
orthologs [18]. Class I HDACs, including HDAC1, 2, 
3 and 8 are predominantly found within the nucleus, 
due to the presence of a nuclear localization sequence 
and the absence of a nuclear export signal sequence 
within HDAC1, 2 and 8. However, HDAC3 has both 
a nuclear import and export signal, allowing for local-
ization in both the cytoplasm and the nucleus [18,19]. 
Class I HDACs have a ubiquitous tissue distribu-
tion [18]. Class II HDACs are subdivided into two 
groups, IIA (HDAC4, 5, 7, 9) and IIB (HDAC6 and 
10), and are predominantly found in the cytoplasm [20]. 
Class II HDACs are able to shuttle between the cyto-
plasm and the nucleus, and have a more tissue-specific 
distribution than class I HDACs [18]. Class IV consists 
only of HDAC11, which shares similarities with both 
Class I and II HDACs. Class I, II and IV HDACs are 
zinc dependent. Class III HDACs are also called sir-
tuins (SIRT1–SIRT7) and are found in the nucleus, 
cytoplasm or mitochondria. Sirtuins act via different 
mechanisms and require the cofactor NAD+ for their 
activity [21]. HDAC enzymes act on nonhistone pro-
teins as well, and can exist in multiprotein complexes 
that influence their activity [22,23]. A summary of the 
HDAC classification is given in Figure 1.
HDAC inhibitors (HDACi) can be grouped into 
different classes based on their chemical structure 
such as hydroxamic acids, aminoanilides, cyclic pep-
tides and short-chain fatty acids. From these, the first 
two classes have been studied most intensively [17]. 
Other classes include ketones, thiols, mercaptoacet-
amides and other types of inhibitors [24,25]. The dis-
tinct features of these classes have been discussed in 
other reviews [26,27]. Three HDACi that are nonse-
lective among the Zn2+-dependent HDACs of the 
hydroxamic acid type, vorinostat, belinostat and pano-
binostat, obtained US FDA approval for treatment 
of hematological cancers [28]. This is also true for the 
cyclic peptide romidepsin [28]. After their introduction 
in cancer therapy, HDACi are gaining attention for 
application in other diseases as well. Their potential 
applications range from neurodegenerative (Alzheimer 
and Huntington disease) to inflammatory diseases 
such as asthma, rheumatoid arthritis and also viral 
infections [29–32]. Interestingly, anti-inflammatory 
effects of HDACi have been reported in a number of 
studies using mouse models of asthma, mostly using 
the nonselective HDACi trichostatin A (TSA), which 
inhibits class I and II HDACs [33]. TSA reduced T-cell 
infiltration and expression of the T
h
2 cytokines IL-4 
and IL-5, and IgE in an ovalbumin sensitization and 
challenge mouse asthma model [34]. In another study, 
the effects of TSA were also evaluated in an ovalbumin 
model. TSA-treated mice had a reduced number of 
total inflammatory cells and eosinophils in the bron-
choalveolar lavage (BAL) fluid compared with vehicle-
treated mice. Furthermore, airway remodeling changes 
were significantly reduced with TSA compared with 
vehicle-treated mice, with fewer goblet cells, less sub-
epithelial collagen deposition and attenuated airway 
hyperresponsiveness induced by methacholine [35]. 
Another study also showed that TSA inhibited metha-
choline-induced airway hyperresponsiveness in mice 
sensitized and challenged with Aspergillus fumigatus 
antigen. However, this was not related to anti-inflam-
matory effects of TSA, since no effects were observed 
on leukocyte trafficking or concentrations of cytokines 
in BAL fluid in antigen-challenged mice. Instead, using 
human precision-cut lung slices and airway smooth 
muscle cells, an inhibiting effect on smooth muscle 
contraction was observed upon TSA treatment [36]. 
In a recent study using an Alternaria mouse allergic 
model, TSA downregulated the number of innate lym-
phoid group 2 cells (ILC2; an important source of the 
cytokines IL-5 and IL-13 which are critical to aller-
gic airway inflammation) expressing IL-5, IL-13 and 
IL-33 upon Alternaria extract challenge, and reduced 
lung eosinophilia and mucus hypersecretion. TSA 
treatment also decreased Alternaria extract-induced 
pro-inflammatory cytokines and chemokines includ-
ing KC (murine IL-8), TNF-α and granulocyte-mac-
rophage colonystimulating factor [37]. Another recent 
study using an ovalbumin mouse model demonstrated 
that TSA decreased IL-17 level in the BAL fluid [38]. 
On the other hand, it was shown that TSA increased 
pro-inflammatory cytokine levels in the culture super-
natant of memory T cells which were isolated from 
ovalbumin asthmatic mice; and when these memory 
T cells (treated with TSA) were adoptively transferred 
into naive mice, increased pro-inflammatory cytokine 
levels were also found in the BAL fluid [39]. Another 
study did not use TSA, but other HDACi including 
www.futuremedicine.com 1015













NAD+ dependent catalytic domain






























































Targeting transcription factor lysine acetylation in inflammatory airway diseases    Review
tubastatin A (an HDAC6i), PCI-34051 (an HDAC8i) 
and the non-selective HDACi givinostat. These were 
tested in a mouse ovalbumin asthma model and all 
reduced inflammatory cell counts in the BAL fluid 
of these mice [40]. Taken together, HDACi generally 
reduce inflammation in mouse asthma models, and 
different mechanisms have been reported for this.
Counterintuitive to these findings, asthma is char-
acterized by increased HAT activity [41]. For instance, 
it was demonstrated that there is increased HAT activ-
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ity, and decreased HDAC activity and HDAC1 and 
HDAC2 expression, in bronchial biopsies and BAL 
macrophages obtained from asthmatics compared 
with healthy adults [42,43], thereby shifting the bal-
ance toward HAT activity. Another study showed 
that HAT activity is increased in peripheral blood 
mononuclear cells (PBMCs) obtained from mild and 
severe asthmatic children compared with healthy chil-
dren, whereas HDAC activity is decreased [44]. How-
ever, another study did not find decreased expression 
of HDAC1 and HDAC2 mRNA or protein in endo-
bronchial biopsies in a large set of severe asthmatics 
compared with healthy controls [45]. Another recent 
study found that in neutrophilic asthma, there was 
increased HAT and decreased HDAC activity in iso-
lated PBMCs. However, there were no differences 
in the expression levels of the HATs p300, KAT2B, 
cAMP response element-binding protein-binding pro-
tein or the HDACs HDAC1, HDAC2 or HDAC3, 
which could indicate differences in activity due to 
post-translational effects [46]. More recently, it has 
been identified that acetylation of histone H3 lysine 18 
(H3K18) is elevated in asthma epithelium compared 
with healthy subjects [47], which is in line with a shift 
toward increased HAT activity.
COPD is characterized by a loss of SIRT1 [48], 
and HDAC2 expression and activity [41,49]. In more 
recent studies, decreased HDAC2 expression was also 
found in PBMCs and lymphocytes in COPD [50,51]. In 
COPD, the decreased HDAC2 expression and activ-
ity can be linked to glucocorticoid resistance [52]. This 
is because glucocorticoids are dependent on HDAC2 
for their immunosuppressive activity. Gluco corticoids 
diffuse through the cellular membrane and bind the 
glucocorticoid receptor (GR) which is present in 
the cytoplasm. The GR is normally bound by heat 
shock proteins, but upon binding of glucocorticoids, 
is released and translocated into the nucleus where it 
binds to target genes with glucocorticoid response ele-
ments. This includes multiple inflammatory genes. GR 
then recruits HDAC2, which leads to transcriptional 
repression [52]. It is interesting to note that also in 
severe asthmatics, there are indications that decreased 
HDAC2 expression and activity can be linked to ste-
roid resistance [53], and that passive smoking reduced 
HDAC2 expression in severe asthmatic children [54].
Altogether, even though HDACi have been reported 
to reduce inflammation in asthma and COPD mod-
els, it should be noted that not much is known about 
the expression and activity of individual HDAC iso-
enzymes in asthma or COPD. The roles of HDACs in 
asthma and COPD need to be more clearly defined. 
Here, we will explore HDACs, cell types, transcrip-
tion factors and mechanisms that have been impli-
cated, in order to shed more light on mechanisms by 
which HDACi could reduce inflammatory responses 
in asthma and COPD. Next to this, we also review 
important methodological developments that allow for 
a better characterization of HDACi targets and selec-
tivity, which will aid in further development of HDACi 
as therapeutic agents for inflammatory lung diseases 
such as asthma and COPD. The topics addressed in 
the review are summarized in Figure 1.
Cell type-specific effects
For several cell types, which have been implicated in 
the inflammatory component of asthma and COPD, 
it is known that these cell types are characterized by 
transcription factors that are crucial to their differenti-
ation and functionality. These transcription factors are 
subject to regulation by acetylation, which determines 
for example the transcription factor stability and DNA 
binding capability. Specific HDACs have been impli-
cated in these processes, which can thereby control 
inflammatory responses. Inhibitors for these enzymes 
can affect these biological processes and thereby mod-
ulate the outcome of inflammatory responses. This 
will be discussed in detail below and is schematically 
represented in Figure 2A, and summarized in Table 1. 
While effects of HDACi on (promoter specific) histone 
acetylation have also been described (e.g., in T cells 
IL-1β induces histone acetylation at the TGF-β-1 pro-
moter, which is further increased by TSA [55]), effects 
on histone acetylation are not the focus of this review.
Macrophages: selective regulation of the 
NF-κB transcription factor acetylation status 
by HDAC3 inhibitors?
Macrophages play a central role in orchestrating 
inflammatory responses in asthma and COPD by 
expressing and secreting pro-inflammatory cytokines 
and chemokines, which then attract other inflamma-
tory cell types [56]. The nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) transcrip-
tion factor plays an important role in this. Upregulated 
NF-κB activity has been reported in asthma [57] and 
COPD [51,58]. NF-κB is subject to regulation by lysine 
acetylations [59]. The p65 NF-κB subunit in particu-
lar is subject to dynamic lysine acetylations, which 
regulate its activity. For example, acetylation of p65 
on lysine (K)310 is required for full transcriptional 
activity. Next to this, acetylations of p65 on K122 
and K123 have been reported to diminish its activity 
due to increased binding to the IκB inhibitor [60–62]. 
The main responsible enzyme for NF-κB acetylation 
is p300; and for deacetylation the enzymes HDAC3 
and SIRT1 have been implicated [60–62]. Interestingly, 
HDACi can regulate the NF-κB transcription factor. 
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Figure 2. Schematic representation of the topics addressed in this review. (A) Macrophages and various 
T lymphocytes have been implicated in inflammatory airway diseases such as asthma and chronic obstructive 
pulmonary disease. These cell types depend on specific transcription factors for their differentiation and 
functionality. Histone deacetylases (HDACs) can affect the acetylation of these transcription factors, which 
influences, for example, the transcription factor stability or its DNA binding capability. HDAC inhibitors (HDACi) 
can influence these biological processes and thereby influence inflammatory responses by these cell types. 
(B) Effects of HDACi on histone acetylation are often used as a read-out indicative of the effects of these 
compounds in cells. However, histone acetylation is not sufficient to (fully) explain the effects of HDACi on 
biological processes such as gene expression. Effects of HDACi on transcription factors and their acetylation status 
may also be particularly important in explaining these effects. (C) Interestingly, selectivity profiles of HDACi are 
commonly elucidated by testing for inhibition of recombinant HDACs. Importantly, however, in cells HDACs are 
known to be present in multiprotein complexes that influence their activity. Importantly, recently, HDACi have 
been reported to have different specificities for such complexes, which adds another layer of complexity to the 
selectivity profile. (D) Different classes of HDACi have been reported to have different binding kinetics with the 
HDACs. Benzamine-based inhibitors have slow binding kinetics, while hydroxamate-based inhibitors have fast 
binding kinetics. This has been demonstrated to translate into biological consequences.
Cell type-specic effects From histones to transcription factors
From recombinant enzymes to HDAC activity in cells From IC50 to binding kinetics
NF-κB
T helper 2 (Th2)
GATA3
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Nonselective HDACi have ambiguous effects on the 
NF-κB pathway [15], and can either activate or dimin-
ish its activity, which results in either increased (as for 
example reported in [63,64]) or reduced (as for example 
reported in [65]) pro-inflammatory gene expression in 
different model systems including mouse OP9 (bone 
marrow derived stromal) cells ([63]), human leukemia 
cells [64] or human non-small-cell lung cancer cells [65].
Also in macrophages, ambiguous effects have been 
described on NF-κB activity and pro-inflammatory 
gene expression for the more selective HDAC1–3 
inhibitor MS-275. It was previously shown that this 
compound increases NF-κB p65 nuclear transloca-
tion, DNA binding, acetylation and activity in U937 
human monocytes [66]. However, MS-275 was shown 
to upregulate IL-10 protein levels, which is important 
in dampening inflammation, in RAW264.7 macro-
phages [67], and to downregulate IL-1β. MS-275 also 
reduced nitric oxide concentration in the media and 
decreased mRNA levels of iNOS and TNF-α, showing 
anti-inflammatory effects [67,68]. MS-275 reduced LPS-
induced IL-1β, IL-6, IL-18 and TNF-α secretion in 
THP-1 human monocytic cells; and nitric oxide secre-
tion in RAW264.7 cells [69]. On the other hand, in bone 
marrow derived macrophages MS-275 showed mainly 
pro-inflammatory effects on gene expression [70]. Thus, 
MS-275 gives rise to either pro- or anti-inflammatory 
effects in these cells. In line with this, we demonstrated 
that MS-275 gives rise to mixed effects on pro- and 
anti-inflammatory gene expression in RAW264.7 
macrophages with upregulation of both pro- and anti-
inflammatory genes [71]. Importantly, MS-275 increased 
anti-inflammatory IL10 expression, and we identified 
NF-κB as a regulator. MS-275 increased NF-κB pro-
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moter activity, acetylation, nuclear translocation and 
NF-κB p65 binding to the IL10 promoter in RAW264.7 
macrophages [71]. This mechanism is in line with litera-
ture that describes that LPS stimulation of macrophages 
activates NF-κB, which induces the expression of IL10 
along with TNFα, IL1β and IL12b [72], which is fur-
ther enhanced by MS-275 in our study. Upon testing 
MS-275 in a mouse COPD (cigarette smoke exposure) 
model, anti-inflammatory effects were observed on sev-
eral parameters including increased anti-inflammatory 
IL10 expression in lung macrophages, reduced KC 
(murine IL-8) expression and reduced neutrophilic 
influx upon MS-275 treatment, which is the first time 
that anti-inflammatory effects of an HDACi are being 
reported in a COPD mouse model [71].
Compared with MS-275, more selective inhibitors 
may have more selective effects on NF-κB-mediated 
inflammatory responses in macrophages. To illus-
trate this, the isoform selectivity profiles on class I 
HDACs of the HDAC3 selective inhibitor RGFP966 
and MS-275 are compared in Table 2. RGFP966 is 
an interesting candidate, based on the important role 
of HDAC3 in deacetylation of specific NF-κB p65 
lysines (including K122 and K123) [73], and our pre-
vious results [74]. RGFP966 increased anti-inflamma-
tory IL-10 expression, and reduced pro-inflammatory 
gene expression in murine precision-cut lung slices. In 
RAW264.7 murine macrophages, pro-inflammatory 
gene expression was decreased, which correlated with 
reduced NF-κB activity [74]. An interesting hypothesis 
is that this could be attributed to the capability of more 
selectively regulating the acetylation status of individ-
ual NF-κB lysines such as K122 and K123 by selective 
HDAC3 inhibitors such as RGFP966.
Next to this, it is worthwhile to mention that the 
HDACs themselves have also been implicated in anti-
inflammatory IL-10 expression by macrophages [5,56]. 
In RAW264.7 macrophages, human THP1 monocytic 
cells and primary human dendritic cells it was shown 
that HDAC11 siRNA upregulates IL10 expression; 
whereas overexpression of HDAC11 has the opposite 
effect. This translated to effects on the antigen-spe-
cific activation of T cells [75]. In another study using 
RAW264.7 macrophages and THP1 monocytic cells, it 
was found that HDAC11 is a transcriptional repressor of 
IL10, whereas HDAC6 is required for IL10 gene tran-
scription in these cells [76]. Intriguingly, IL-10 itself can 
inhibit LPS-induced CXCL8 expression in monocytes, 
via a mechanism that involves HDAC2. IL-10 increased 
the association of HDAC2 with the CXCL8 promoter 
region, which resulted in reduced CXCL8 expression [77]. 
This illustrates that individual HDACs have specific 
roles in the control of anti-inflammatory IL10 expression 
(with HDAC11 as an interesting possible target due to its 
inhibitory role in IL10 expression), and in the inhibition 
of CXCL8 expression by IL-10 in these cells.




Compound Effects in lung inflammation models Ref.
NF-κB/macrophages HDAC1–3 inhibitor MS-275 Ambiguous effects [66–71]
NF-κB/macrophages HDAC3 inhibitor RGFP966 Attenuation of Inflammation [74]
GATA3/Th2 cells SIRT1 inhibitor Sirtinol Increased Th2 related expression in T cells from cord blood; and 
in PBMCs from severe asthmatics 
 Enhanced acetylation and activity of the GATA3 transcription 
factor in HUT78 T lymphocytes
[83]
GATA3/Th2 cells SIRT1 activator (SRT2172) Reduced IL-4 mRNA expression in PBMCs from ten patients with 
severe asthma
[83]
Foxp3/Tregs HDAC6i ACY-738 and SIRT1 
inhibitor EX-527
Increased Treg suppressive function (in combination and alone) 
 EX-527 increased acetylation of K31, K262 and K267, and 
increased the stability and levels of the transcription factor
[91,96]
Foxp3/Tregs HDAC1–3 inhibitor MS-275 Ambiguous effects [98–100]
RORγt/Th17 HDAC1–3 inhibitor MS-275 Enhanced Th17 differentiation in mouse splenocytes [106]
RORγt/Th17 Pan HDACi givinostat Downregulated the IL-6 receptor on T cells that reduced their 
ability to differentiate into Th17 cells, but instead skewed 
differentiation toward the Treg phenotype
[107]
Foxp3 and RORγt Pan HDACi TSA Increased Foxp3 and decreased RoRγt levels in an ovalbumin 
challenge asthma mouse model
[38]
HDAC: Histone deacetylase; HDACi: Histone deacetylase inhibitor; PBMC: Peripheral blood mononuclear cell; TSA: Trichostatin A.
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Furthermore, there is impaired phagocytosis of 
bacteria and virus-infected cells by macrophages in 
asthma and COPD, which can cause adverse effects 
in patients [78]. It was shown that depending on the 
treatment regime, HDACi can improve bacterial clear-
ance of macrophages. The HDAC6-selective inhibitor 
tubastatin A promoted bacterial clearance from human 
macrophages, whereas the class I HDACi MS-275, 
which inhibits HDAC1–3, had no effect on intracel-
lular bacterial loads. Although the mechanisms remain 
unclear, this suggests a role for HDAC6 in bacterial 
clearance by macrophages [79].
In summary, macrophages are an important cell type 
in the inflammatory responses in asthma and COPD. 
The NF-κB transcription factor plays an important 
role in the pro-inflammatory gene expression in mac-
rophages, and is subject to regulation by acetylation. 
Nonselective HDACi have ambiguous effects on the 
NF-κB transcription factor, which translates into 
either pro- or anti-inflammatory outcomes. This is 
also the case for the HDAC1–3 inhibitor MS-275 in 
macrophages. More selective inhibitors, such as the 
HDAC3 inhibitor RGFP966, however, may have more 
selective effects on gene expression due to more selec-
tive regulation of the acetylation status of the NF-κB 
transcription factor. This inhibitor causes downregula-
tion of pro-inflammatory gene expression, but upregu-
lates IL-10 expression. Next to this, HDACs also play 
an important role in anti-inflammatory IL-10 expres-
sion in macrophages. An example in this respect is the 
inhibitory role of HDAC11 in IL-10 expression. Fur-
thermore, HDACi can also improve bacterial clearance 
in macrophages, which is relevant because bacterial 
clearance is impaired in asthma and COPD patients. 
Finally, the studies described above also demonstrate 
that the selectivity profile of an HDACi matters for the 
outcome on inflammatory responses in macrophages.
Th2 cells: regulation of the GATA3 
transcription factor acetylation status by an 
SIRT1 inhibitor or activator
T
h
2 cells are considered to be important drivers of 
asthma due to production of cytokines such as IL-4 
(which regulates the allergen-specific synthesis of IgE), 
and IL-5 (which recruits eosinophils) among  others [2]. 
Roles for HDACs have been described in T
h
2 cell 
mediated inflammatory responses in asthma. One 
study showed that conditional knockout of HDAC1 in 
T cells in a mouse ovalbumin asthma model resulted 
in increased eosinophil recruitment into the lung, 
mucus hypersecretion, parenchymal lung inflammation 
and enhanced airway resistance. This correlated with 
enhanced expression of T
h
2-related cytokines in T cells 
isolated from these mice [80]. This indicates an inhibit-
ing role for HDAC1 in T
h
2-related cytokine expression. 
Next to this, for the differentiation of T lymphocytes 
into T
h
2 cells, GATA3 is an essential transcription fac-
tor [81], which is regulated by acetylation [82]. GATA3 
has been described to be acetylated by the HAT p300 on 
K305, which increases its activity [82]. For deacetylation 
of GATA3, SIRT1 has been implicated in another study 
where the SIRT1 inhibitor sirtinol increased T
h
2-related 
expression in T cells from cord blood [83]. This correlated 
with enhanced acetylation and activity of the GATA3 
transcription factor in another T-cell line (HUT78 
T lymphocytes) upon sirtinol treatment (although it 
was not studied on which lysine) [83]. Importantly, this 
study also showed that SIRT1 is decreased in activity 
and expression at the protein level in whole cell extracts 
from PBMCs isolated from severe asthmatic patients. 
No decrease was observed for the other sirtuin members 
(SIRT2, SIRT3, SIRT6 and SIRT7). Sirtinol was tested 
in these PBMCs and increased T
h
2 cytokine expression. 
Furthermore, an SIRT1 activator (SRT2172) signifi-
cantly reduced IL-4 mRNA expression in PBMCs from 
ten patients with severe asthma [83]. Taken together 
SIRT1 plays a role in inhibiting T
h
2 differentiation in 
T cells, by regulating the acetylation status of GATA3. 
The decreased SIRT1 expression in severe asthmatics 
could contribute to sustained T
h
2 cytokine expression 
such as IL-4, raising interest for SIRT1 as a target for the 
treatment of severe asthma.
Tregs: regulation of the Foxp3 transcription 
factor acetylation status by HDACi
Tregs can dampen inflammation through diminish-
Table 2. IC50 values of histone deacetylase 1–3-selective inhibitor MS-275 and histone deacetylase 
3-selective inhibitor RGFP966 for recombinant class I human histone deacetylases.
HDAC inhibitor HDAC 1 HDAC 2 HDAC 3 HDAC 8
MS-275† 0.19 ± 0.04 0.41 ± 0.09 0.95 ± 0.19 76.5 ± 10.1
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ing the function of other T cells, which is important 
in controlling immune homeostasis [84]. A number 
of studies have suggested that Tregs are impaired in 
activity in asthma [85,86]. In COPD, there are indica-
tions that the number of Tregs is reduced [1]. How-
ever, the role of Tregs in asthma and COPD has to be 
better defined. A study by Baru et al. demonstrated 
that the timing of the effects of Tregs is important to 
the outcome of inflammatory responses in an asthma 
model. The group demonstrated that Treg depletion 
during the allergen challenge phase did not change 
the airway inflammatory response, but there was an 
increased inflammatory response upon Treg depletion 
during the sensitization phase [87]. Foxp3 is a tran-
scription factor, which is crucial in the commitment 
of T cells in differentiating into Tregs. Reduced Foxp3 
expression was observed in PBMCs from elderly asth-
matics [88]. There is an important role for acetylation 
and deacetylation of Foxp3 in the regulation of this 
transcription factor [89,90] including on K31, K262 
and K267 [91]. It has been identified that p300 and 
Tip60 can acetylate Foxp3 (intriguingly, p300 and 
Tip60 work together to acetylate one another and 
Foxp3) [92]. Acetylation of Foxp3 increases its resis-
tance to ubiquitination and proteasomal degradation, 
and increases DNA binding [89]. Foxp3 is deacetylated 
by SIRT1 and HDAC9 which has the opposite effect, 
and therefore impairs Treg differentiation. Next to 
this, HDAC6 also plays an important indirect role, 
through the deacetylation of heat shock proteins, 
which can then decrease the stability of Foxp3 [93]. 
More recently, it has been discovered that HDAC3 
also plays a promoting role in the differentiation of 
Tregs by suppressing IFN-γ (ifng) and IL-12 produc-
tion (which both need to be suppressed for proper 
differentiation) [94]. Clearly HDACs play an impor-
tant role in the differentiation and functionality of 
Tregs. Several reports have described that HDACi can 
affect the differentiation and regulatory capacity of 
Tregs, which has mostly been described for nonselec-
tive HDACi [95]. More selective inhibitors have also 
been studied. One study used the HDAC6i ACY-738 
and the SIRT1 inhibitor EX-527 in mice, and found 
these compounds to increase Treg-suppressive func-
tion (in combination and alone) [96]. There has also 
been interest in the development of novel HDAC6i 
for augmentation of Treg-suppressive function [97]. 
Furthermore, Sirt1 inhibitor EX-527 was used in a 
study where acetylation sites were identified on Foxp3 
(K31, K262 and K267), and increased acetylation of 
these lysines as well as the stability and levels of the 
transcription factor [91]. HDAC1–3 inhibitor MS-275 
increased Foxp3 expression in T cells isolated from 
human blood [98]. In other studies focusing on can-
cer models, however, downregulated Foxp3 expres-
sion by Tregs has also been reported upon MS-275 
treatment [99,100]. These discrepancies can likely be 
explained by the different model systems, concentra-
tions and methods of administration of MS-275 used. 
It could be that inhibition of HDAC6 or SIRT1 as 
opposed to inhibition of class I HDACs 1–3 gives rise 
to less ambiguous outcomes, and can augment Treg 
function and differentiation. This opens up an inter-
esting novel line of research to define the effects of 
selective HDACi on Treg function in the diseases such 
as asthma and COPD.
Can HDACi alter the balance between Tregs 
& Th17 cells?
A more recently discovered subset of T cells are the 
Th17 cells, which are believed to play a role in asthma 
and COPD pathogenesis [101,102], although the role 
needs to be more clearly defined. Th17 cells are an 
important source of the pro-inflammatory cytokine 
IL-17, and IL-17 levels were found to be increased 
in sputum of asthmatic patients [101–103]. The role of 
Th17 cells and IL-17 in COPD is much less clear [101]. 
The RORγt transcription factor is essential for the 
differentiation of the Th17 cell type [104], and has 
been reported to be regulated by acetylation in a 
recent study. It was demonstrated that p300 acety-
lates RORγt at K81 (increasing its activity), whereas 
HDAC1 reduces acetylation of RORγt (which 
decreases its activity, although it was not studied which 
lysine was involved) in HEK293T cells and isolated 
naive T cells from healthy human subjects [105]. In 
line with this, MS-275 has been reported to enhance 
Th17 differentiation in mouse splenocytes [106]. On 
the other hand, the HDACi givinostat downregulated 
the IL-6 receptor on T cells which reduced their abil-
ity to differentiate into Th17 cells, but instead skewed 
differentiation toward the Treg phenotype [107]. Inter-
estingly, in line with this, in a study using an ovalbu-
min challenge asthma mouse model, on the mRNA 
level TSA increased Foxp3 and decreased RoRγt 
levels. There were also decreased numbers of inflam-
matory cells in BAL fluid, and decreased IL-4, upon 
TSA treatment, as well as decreased IgE in the serum. 
In the same study, in Jurkat T cells, upon TSA treat-
ment, the Foxp3 mRNA level was upregulated, while 
the RORγt mRNA level was downregulated. The 
Foxp3 protein level was also upregulated by TSA, 
on the whole suggesting that TSA can alter the bal-
ance of Th17/Treg cells in this study [38]. Altogether, 
the hypothesis that HDACi could shift the balance 
from Th17 to Treg cells is interesting since this might 
have advantageous effects in the context of asthma 
and COPD, and calls for further research along this 
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line. However, future investigations will need to 
further elucidate the specific HDACs involved, and 
demonstrate whether targeting the balance of Th17/
Treg cells using HDACi could ultimately be a viable 
 therapeutic strategy.
From histones to transcription factors
It is interesting to note that the effects of HDACi on 
histone acetylation are oftentimes used as a read-out 
indicating the effects of these inhibitors in cells. How-
ever, the studies discussed above indicate that effects 
of HDACi on transcription factors and their acetyla-
tion status are also important to the outcome in disease 
models, including those for asthma and COPD. Sev-
eral studies also indicate that effects on histone acetyla-
tion do not always correlate with effects on biological 
processes such as gene expression. For example, upon 
HDACi treatment, some genes have been reported 
to be upregulated, while others go down (roughly as 
many go up as down), whereas global histone acetyla-
tion is generally pronouncedly increased [108]. Interest-
ingly, the balance between effects on histone acetyla-
tion and gene expression also changes depending on 
the employed incubation time [109]. In HeLa cells 
(ATCC® CCL-2™) it was demonstrated that valproic 
acid and suberanilohydroxamic acid (SAHA) have 
an early onset effect on gene expression after 12 h of 
incubation. Upon 48 h of incubation, these changes in 
gene expression had returned to baseline levels, while 
increases in histone acetylation had not [109]. Another 
study found that upon HDACi treatment there was a 
precisely timed increase in histone H3 lysine 27 tri-
methylation (H3K27me3) at transcription start sites, 
but little or no increase in histone acetylation, whose 
role seemed to be to provide a stable chromatin envi-
ronment that allows transcription to be modified by 
other factors [110]. In another study, the nonselective 
HDACi romidepsin and SAHA were tested in differ-
ent cancer cell lines, and their effects on histone acety-
lation were investigated together with their effects on 
apoptosis [111]. Treatment with romidepsin or SAHA 
for 6 h caused similar increases in histone acetylation 
in all cell lines, but not all of the cell lines under-
went apoptosis upon romidepsin or SAHA treatment. 
Therefore, the effects on histone acetylation did not 
correlate with effects on apoptosis in all cell lines [111]. 
In summary, recent research indicates that HDACi-
induced changes in histone acetylation cannot (fully) 
explain their effects on gene expression and apoptosis. 
Effects of HDACi on the acetylation status of specific 
transcription factors may therefore be particularly 
important in explaining their effects in disease mod-
els, such as those for asthma and COPD (a schematic 
 representation is given in Figure 2B).
From recombinant enzymes to HDAC activity 
in cells
Isoenzyme selectivity of HDACi has important con-
sequences for their effects. Hence, development of 
highly potent molecules selectively targeting specific 
HDACs or a select group of HDACs is important. 
This is likely important in obtaining selective effects 
on specific pathways such as the NF-κB pathway in 
the context of asthma and COPD models, which 
occurs through fine-regulation of its acetylation on 
specific lysines [73]. A selectivity profile for HDACi is 
generally obtained by testing the inhibition on recom-
binant HDAC enzymes [33]. However, it has become 
apparent that several other factors need to be taken 
into account. First, it has been demonstrated that 
binding characteristics of HDACi in cells differ from 
the profile on recombinant enzymes due to the fact 
that HDACs exist in multiprotein complexes, add-
ing another level of complexity. For example, one 
study used a chemoproteomics strategy, where an 
affinity capture method was employed using Sepha-
rose beads derivatized with HDACi hydroxamic acid 
analogs [112]. This allowed for a competition binding 
assay, where extracts of cells treated with increasing 
HDACi concentration competed with the immobi-
lized HDACi analog probe matrix for binding protein 
targets. The reduction in protein capture resulting 
from the competition with the increasing concentra-
tion of the ‘free inhibitor’ was quantified by mass spec-
trometry using isobaric tandem mass tags [112]. Target 
protein complexes interacting with HDACi could be 
identified, and importantly, inhibitor selectivity for 
native drug target complexes deviated from literature 
values obtained using recombinant enzymes, revealing 
an unexpected degree of selectivity of certain HDACi. 
For example, aminoanilide-based inhibitors displayed 
a preference for the HDAC3–NCoR complex [112]. As 
a side-note, interestingly, chemoproteomic approaches 
also enable the identification of possible off-targets of 
HDACi [112]. Another option to investigate HDACi 
specificity is to analyze HDACi-induced changes at 
the level of all lysine acetylation sites (acetylome). A 
study from Scholz et al. elucidated the selectivity pro-
file of HDACi at the level of the global acetylome [113]. 
HeLa cells were treated with a panel of widely used 
HDACi and changes at the acetylome were monitored 
by quantitative bottom-up proteomics. Stable isotope 
labeling with amino acids in cell culture (SILAC) 
was combined with enrichment of acetylated peptides 
using anti-acetyllysine antibodies and analysis by mass 
spectrometry. The fraction of upregulated acetylation 
sites in HDACi-treated cells was greater than the frac-
tion of downregulated sites [113]. For several HDACi, 
the number of acetylation sites affected was not pro-
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portional to the number of HDACs they were found to 
inhibit when testing on recombinant HDACs, which 
is in line with chemoproteomics studies demonstrating 
unexpected selectivities of HDACi for multiprotein 
complexes (as for example, described in [112]). In prin-
ciple, differential proteomics approaches as described 
by Scholz et al [113] enable to elucidate HDACi selec-
tivity profiles at the level of the nuclear, cytosolic or 
mitochondrial acetylome. We envision that a better 
characterization of HDACi targets and specificities 
is necessary for the further development of HDACi 
as potential therapeutics for diseases, such as asthma 
and COPD. Considering the described developments, 
this can be done by generating a selectivity profile on 
HDACs in cells, which can be complemented with 
acetylome analysis (a schematic representation is given 
in Figure 2C).
From IC50 to binding kinetics
Next to these studies into selectivity profiles, there has 
been a study into the binding kinetics of HDACi with 
recombinant HDACs [114]. A reporter displacement 
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 were slow for the aminoanilides. 
Therefore, aminoanilides displayed slow, whereas 
hydroxamic acids displayed fast binding kinetics [114]. 
The effects upon washout of the inhibitors were then 
tested in the neuroblastoma cell line SH-SY5Y; after 
a ‘pulse’ treatment with the inhibitors for 6 h and 
replacement of the medium with a drug-free medium. 
In line with slow binding kinetics for aminoanilides, 
a sustained state of histone hyperacetylation was 
observed for the aminoanilide-based inhibitor MS-275 
after washout (which was still observed after 96 h), 
while upon treatment with the hydroxamic acid-based 
inhibitors, acetylation returned to baseline levels much 
faster (within 18 h) [114]. Becher et al. reported simi-
lar findings using a chemoproteomic approach which 
allowed for a comparison of time-dependent binding 
of hydroxamic acid-based and aminoanilide-based 
HDACi [115]. Also in line with this, another study 
using MS-275 found this compound to have a long 
lasting effect on histone acetylation of histone H4 
lysine 12 (H4 K12) after washout [116]. These stud-
ies indicate that the binding kinetics of HDACi have 
biological consequences, which is a point that needs 
to be taken into account next to the selectivity pro-
file of HDACi, since it is important in evaluating their 
therapeutic utility (a schematic representation is given 
in Figure 2D).
Conclusion & future perspective
Currently, HDACi are being used in the treatment of 
cancer. However, these compounds have anti-inflam-
matory properties at lower concentrations than those 
used for cancer treatment [117]. Hence, HDACi have 
gained interest as therapeutic agents in other areas, 
including inflammatory airway diseases such as asthma 
and COPD. Studies indicate that HDACi can reduce 
inflammation in mouse asthma and COPD models. 
Counterintuitive to these observations, both diseases are 
characterized by increased HAT and decreased HDAC 
activity. However, little is known about the expression 
and activity of individual HDACs in asthma and COPD. 
Next to this, research should focus on further elucidat-
ing the role of protein acetylation and deacetylation in 
driving the initiation and progression of these diseases. It 
is therefore a field of study that urgently needs attention.
Interestingly, HDACi have been demonstrated to be 
able to affect the differentiation and functionality of 
immune cell types that have been implicated in asthma 
and COPD. These include macrophages and vari-
ous T lymphocytes. A common phenomenon is that 
HDACs play a role in the regulation of transcription 
factors such as NF-κB and Foxp3 in these cell types. 
These transcription factors are crucial in determining 
cell functionality and the outcome in terms of inflam-
matory responses. Through deacetylation of critical 
lysine residues of these transcription factors, HDACs 
can affect, for example, transcription factor stability, 
nuclear translocation and DNA binding. HDACi can 
influence these biological processes and thereby affect 
inflammatory gene expression. It has become clear that 
these effects of HDACi are cell type specific, and that 
selective inhibition of HDACs is important. The effects 
of HDACi on transcription factors and their acetylation 
status may be particularly important. Previous studies 
oftentimes focused extensively on characterizing effects 
of HDACi on histone acetylation; however, this is not 
sufficient to fully explain the effects of HDACi on bio-
logical processes such as gene expression. Inhibitors 
that are highly potent as well as isoform selective can 
aid in elucidating the roles of individual HDACs, next 
to their potential as therapeutics for these diseases.
A number of important insights have been acquired 
in recent years. For example, it is important to study 
the selectivity profile of HDACi in cells, since the inhi-
bition at the level of recombinant HDACs has been 
shown to vary from the inhibition on HDACs in cells 
which are present in multiprotein complexes. A selectiv-
ity profile can also be generated at the level of the acety-
lome. Mass spectrometry has been particularly useful 
in allowing these kind of analyses, which allows for a 
better characterization of HDACi targets and selectiv-
ity at different levels complementing each other. Next 
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Executive summary
Background
•	 Alternative treatments for the inflammatory airway diseases such as asthma and chronic obstructive 
pulmonary disease (COPD) can be found by studying underlying biological processes. This may include 
epigenetic regulation, such as lysine acetylation.
•	 Lysine acetylation is a post-translational modification of proteins, which regulates protein activity. Lysine 
acetylation, in turn, is regulated by histone acetyltansferases (HATs) as writers and histone deacetylases 
(HDACs) as erasers.
•	 The nonselective HDAC inhibitor (HDACi) trichostatin A (TSA) attenuates inflammation in mouse asthma 
models.
•	 Counterintuitive to this, asthma and COPD are both characterized by increased HAT activity and decreased 
HDAC activity.
•	 The expression and activity of individual HAT and HDAC isoforms in asthma and COPD need to be further 
elucidated.
•	 The biological mechanisms by which HDACi can attenuate inflammation in models for airway inflammation 
need to be further elucidated.
Cell type-specific effects
•	 HDACs play a role in the regulation of acetylation of transcription factors in specific cell types implicated in 
asthma and COPD, which determines cell functionality and the outcome in terms of inflammatory responses. 
HDACi can affect these processes.
Macrophages: selective regulation of the NF-κB transcription factor acetylation status by HDAC3 
inhibitors?
•	 In macrophages, nonselective HDACi have ambiguous effects on the NF-κB pathway, and can either up- or 
downregulate pro-inflammatory gene expression.
•	 The HDAC1–3 inhibitor MS-275 upregulates both pro- and anti-inflammatory gene expression in macrophages.
•	 The HDAC3 inhibitor RGFP966 gives rise to only anti-inflammatory effects. This could be due to more selective 
regulation of NF-κB acetylation by HDAC3 inhibitors such as RGFP966.
Th2 cells: regulation of the GATA3 transcription factor acetylation status by an SIRT1 inhibitor or activator
•	 In Th2 cells, SIRT1 has been implicated in the deacetylation of GATA3.
•	 SIRT1 is decreased in activity and expression in isolated cells from severe asthmatic patients.
•	 A SIRT1 inhibitor (Sirtinol) enhances Th2-related cytokine expression, whereas an SIRT1 activator (SRT2172) 
reduces Th2-related cytokine expression, in these isolated cells, raising interest for SIRT1 as a target for the 
treatment of severe asthma.
Tregs: regulation of the Foxp3 transcription factor acetylation status by HDACi
•	 In Tregs, SIRT1 and HDAC9 deacetylate Fop3, which reduces the stability and activity of this transcription 
factor.
•	 In line with this, HDACi can augment the differentiation and regulatory capacity of Tregs, raising interest in 
further research along these lines.
to studying IC
50
 values, it is important to take thermo-
dynamic and kinetic parameters into account, such as 
the residence time of HDACi in recombinant HDACs, 
which has been shown to vary between hydroxamic 
acid and aminoanilide type HDACi.
Altogether, the studies discussed indicate that 
HDACi have great potential for the treatment of inflam-
matory airway diseases. However, a clinical application 
for HDACi in this field is still far from within reach. 
The recent insights as discussed above are crucial in the 
future development of more selective HDACi, and will 
drive the development of such HDACi. This is essen-
tial in broadening their application toward inflamma-
tory lung diseases such as asthma and COPD. Finally, 
future steps must also include further elucidation of the 
effects of HDACi in more advanced disease models, 
particularly for COPD.
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